Psychedelic Drugs Market, By Drug Type, By Application, By Distribution Channel, By Route of administration, By Geography

Description

The Global Psychedelic Drugs Market is estimated to be valued at USD 3.41 Bn in 2024 and is expected to reach USD 8.32 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 13.6% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 3.41 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	13.60%	2031 Value Projection:	US$ 8.32 Bn

Figure. Psychedelic Drugs Market Share (%), By Region 2024

The global psychedelic drugs market has witnessed significant growth in the past few years due to the increasing acceptance of psychedelic-assisted psychotherapy for the treatment of mental health conditions. Psychedelic drugs such as lysergic acid diethylamide (LSD), psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), ketamine, and dissociative drugs are used to alter users' perceptions, thoughts, and consciousness levels. Increasing prevalence of depression and other mental disorders as well as growing number of clinical research to evaluate the efficacy of psychedelic drugs for treatment of various mental health disorders is primarily driving the market growth. Moreover, favorable regulatory reforms by several governments across North America and Europe have positively impacted the adoption of psychedelic therapeutics for treatment of conditions such as treatment-resistant depression.

Market Dynamic:

The global psychedelic drugs market growth is primarily driven by factors such the increasing prevalence of mental disorders, ongoing drug development and clinical research related to psychedelic drugs, and growing acceptance of psychedelic-assisted psychotherapy among physicians and patients. According to the WHO estimates, over 264 million people suffer from depression globally. Psychedelic drugs such as psilocybin, LSD, and MDMA have shown potential for the treatment of major depressive disorder as well as other mental health conditions. The growing number of clinical studies to evaluate the therapeutic effects of these drugs for conditions like treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD) is fostering the market growth. Additionally, supportive regulatory framework in several developed economies is enabling the commercialization of psychedelic medicines. However, strict regulations regarding the clinical and commercial use of these drugs pose potential challenges for the market. Moreover, risk of legalized recreational use can restrain the therapeutic adoption of psychedelic drugs. Meanwhile, the development of evidence-based treatment paradigms by facilitating research and innovation represents an opportunity for stakeholders in this market.

Key features of the study:

This report provides an in-depth analysis of the global psychedelic drugs market and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global psychedelic drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include MindMed, Compass Pathways, Cybin Inc., Atai Life Sciences, Field Trip Health Ltd., Havn Life Sciences, Revive Therapeutics, NeonMind Biosciences, Numinus Wellness, PharmaTher Holdings Ltd., Jazz Pharmaceuticals, Seelos Therapeutics, NRx Pharmaceuticals Inc., Psyched Wellness Ltd., and Silo Wellness,

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global psychedelic drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global psychedelic drugs market.

Market Segmentation

By Drug Type Insights (Revenue, USD Bn, 2019 - 2031)
- Gamma Hydroxybutyric Acid (GHB)
- Ketamine
- Psilocybin
- Lysergic Acid Diethylamide (LSD)
- 3,4-Methylenedioxymethamphetamine (MDMA)
- Other Drug Types (Mescaline, etc.)
By Application Insights (Revenue, USD Bn, 2019 - 2031)
- Mental Health Disorders
- Depression
- Anxiety
- PTSD (Post-Traumatic Stress Disorder)
- Substance Use Disorders
- Neurological Disorders
- Alzheimer's Disease
- Parkinson's Disease
- Pain Management:
- Chronic Pain
- Migraines
- Other Applications:
- Obsessive-Compulsive Disorder (OCD)
- Others (Opiate Addiction, etc.)
By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
- Oral
- Intravenous
- Inhalation
- Intranasal
- Others (Rectal)
Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- MindMed
- Compass Pathways
- Cybin Inc.
- Atai Life Sciences
- Field Trip Health Ltd.
- Havn Life Sciences
- Revive Therapeutics
- NeonMind Biosciences
- Numinus Wellness
- PharmaTher Holdings Ltd.
- Jazz Pharmaceuticals
- Seelos Therapeutics
- NRx Pharmaceuticals Inc.
- Psyched Wellness Ltd.
- Silo Wellness

Product Code: CMI7527

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Psychedelic Drugs Market, By Drug Type
- Global Psychedelic Drugs Market, By Application
- Global Psychedelic Drugs Market, By Distribution Channel
- Global Psychedelic Drugs Market, By Route of Administration
- Global Psychedelic Drugs Market, By Region

3. Market Dynamics, Regulations, And Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Psychedelic Drugs Market, By Drug Type, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Gamma Hydroxybutyric Acid (GHB)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Ketamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Psilocybin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Lysergic Acid Diethylamide (LSD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
3,4-Methylenedioxymethamphetamine (MDMA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Other Drug Types (Mescaline, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Psychedelic Drugs Market, By Application, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Mental Health Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Depression
Anxiety
PTSD (Post-Traumatic Stress Disorder)
Substance Use Disorders
Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Alzheimer's Disease
Parkinson's Disease
Pain Management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Chronic Pain
Migraines
Other Applications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Obsessive-Compulsive Disorder (OCD)
Others (Opiate Addiction, etc.)

6. Global Psychedelic Drugs Market, By Distribution Channel, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Psychedelic Drugs Market, By Route of Administration, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Inhalation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others (Rectal)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Psychedelic Drugs Market, By Region, 2019 - 2031, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

MindMed
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Compass Pathways
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cybin Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Atai Life Sciences
Field Trip Health Ltd.
Havn Life Sciences
Revive Therapeutics
NeonMind Biosciences
Numinus Wellness
PharmaTher Holdings Ltd.
Jazz Pharmaceuticals
Seelos Therapeutics
NRx Pharmaceuticals Inc.
Psyched Wellness Ltd.
Silo Wellness

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us